**Table 4.** Blood analysis comparison between baseline and HT treatments.

|  |  |  |
| --- | --- | --- |
|  | **Baseline****Mean ± DS** | **HTT****Mean ± DS** |
| Total Cholesterol (mg/dl) | 156.54 ± 11.91 | 152.86 ± 12.13\* |
| HDL-C (mg/dl) | 62.10 ± 8.95 | 62.21 ± 9.34 |
| Triglycerides (mg/dl) | 66.45 ± 27.28 | 58.50 ± 26.57\* |
| LDL-C (mg/dl) | 87.05 ± 9.94 | 86.57 ± 11.92 |
| Glycemia (mg/dL) | 80.02 ± 7.51 | 79.86 ± 5.28 |
| Insulin (U/mL) | 6.68 ± 2.76 | 6.98 ± 3.00 |
| Total Cholesterol/HDL-C | 2.54 ± 0.29 | 2.50 ± 0.34\* |
| Total Cholesterol/LDL-C | 1.79 ± 0.22 | 1.78 ± 0.18 |
| LAP | 10.04 ± 3.64 | 9.80 ± 3.55 |
| LDL/HDL | 1.40 ± 0.28 | 1.42 ± 0.31 |

All parameters were evaluated before and after treatment. All results are expressed as mean ± standard deviation (SD). Statistical significance attributed to results with \*p<0.05 (between HTT and Baseline) after parametric test (student t-test) or non-parametric test (Wilcoxon-Mann-Whitney).

AP: acute phase; HTT: hydroxytyrosol treatment; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.